Biomarkers for Early Diagnosis of Alzheimer's Disease: Current Status and Future Directions

Abstract

Alzheimer's disease (AD) is a progressive neurological disease that leads to loss of cognitive function and a significant deterioration in the quality of life. Early diagnosis plays a critical role in providing timely treatment and managing symptoms, which underscores the need to develop accurate and sensitive biomarkers to detect disease at an early stage.

Major key biomarkers, such as beta-amyloid and tau protein, have been the subject of intense research in recent decades. They reflect the pathological processes occurring in the brain of patients with AD, and can be used to assess the risk of developing and progressing the disease. However, the exact mechanisms of formation and accumulation of these biomarkers require further investigation.

This article provides an overview of the current state and future research directions on biomarkers for the early diagnosis of AD. Various research methods are considered, including neuroimaging, biochemical analyses, and genetic approaches aimed at identifying new and improving existing biomarkers.

Recent studies have shown that the combination of several biomarkers can significantly improve the accuracy of AD diagnosis and predict the likelihood of developing the disease in the early stages. The use of modern analytical technologies, such as mass spectrometry and genome sequencing, contributes to the expansion of the arsenal of tools for the study and use of biomarkers in clinical practice.

However, to fully integrate biomarkers into diagnostic and therapeutic algorithms, a number of challenges must be overcome, including standardizing methods, improving the availability of testing, and evaluating the ethical and legal aspects of using biomarkers.

In conclusion, further research on biomarkers for the early diagnosis of AD represents a promising direction that has the potential to significantly change the practice of clinical neurology. It is expected that the development and validation of new biomarkers will improve the diagnosis, prediction and monitoring of AD, which will affect the improvement of treatment outcomes and patient care.